[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

China Blood Products Market to Record Over 10% CAGR to 2022, States CRI in Its New Report Published at MarketPublishers.com

21 Nov 2017 • by Natalie Aster

LONDON – The concentration of the world blood product industry is quite high. The 4 enterprises of developed countries (Baxter, CSL Behring, Octapharma, and Grifols) capture more than 80% of the overall market. To date, the world blood industry keeps on observing relatively sustainable growth, with emerging markets acting as key driving forces. 

China is set to turn into one of the leading blood product markets with its economic development. The country’s government imposes rigid regulations on production, import and sales of blood products. Additionally, the government implements a system of lot release of biological products (encompassing blood derived products and vaccines), mandatorily examining and verifying different batches of such products when leaving factory or being imported. Disqualified or disapproved blood products should not be available commercially or imported. 

The Chinese blood products market has amounted to around USD 3.02 billion by value in 2017, and is projected to increase at an estimated CAGR of more than 10% from 2018 to 2022.

New research report “Research Report on Blood Product Industry in China, 2018-2022” elaborated by CRI provides an insightful analysis of the industry on a national level.

The study offers an all-round overview of the status of world blood product industry, and further gives insights into the development status of the blood product industry in China.

The report discusses the political climate and lot release system of the country’s industry. It provides an analysis of the status of segmented blood products in China; reviews the competition status of the industry. Furthermore, the research report presents information on the top blood product producers in China and limelights their operation status. It reviews the blood products exported from Baxter, CSL Behring, Octapharma and Grifols S.A. to China. The research report discusses the price trends of raw materials and finished products; canvasses the driving factors and opportunities with respect to the market; pinpoints the risks and challenges faced by the domestic blood product industry. Detailed forecast on supply and demand of blood products in the country to 2022 are also available in the study.

More new research reports elaborated by CRI can be found in this catalogue.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected] 

Analytics & News

Weekly Digest